Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain.
Article Details
- CitationCopy to clipboard
Witenko C, Moorman-Li R, Motycka C, Duane K, Hincapie-Castillo J, Leonard P, Valaer C
Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain.
P T. 2014 Jun;39(6):427-35.
- PubMed ID
- 25050056 [ View in PubMed]
- Abstract
For patients with low back pain, skeletal muscle relaxants are often initiated after failure of first-line analgesics. However, these medications (reviewed in this article) are controversial alternatives that carry risks of adverse effects and increased cost.
DrugBank Data that Cites this Article
- Drugs
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Cyclobenzaprine Cytochrome P450 3A4 Protein Humans UnknownSubstrateDetails - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareOrphenadrineBotulinum toxin type B Botulinum toxin type B may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. OrphenadrineTryptophan Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. OrphenadrineFluvoxamine Fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. OrphenadrineLorazepam Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. OrphenadrineEthchlorvynol Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.